| ANAVEX LIFE SCI. DL-,001 |
| USA |
| Gesundheit |
| US0327973006 / A1411S |
| 12X1 (Frankfurt) / AVXL (NASDAQ) |
| FRA:12X1, ETR:12X1, 12X1:GR, NASDAQ:AVXL |
| - |
| https://www.anavex.com/ |
|
Anavex Life Sciences Corp. is a biopharmaceutical company dedicated to the development of novel therapies for the treatment of neurodegenerative and central nervous system diseases. The primary functi..
>Volltext.. |
| 327.44 Mio. EUR |
| 215.16 Mio. EUR |
| - |
| -37.88 Mio. EUR |
| -33.93 Mio. EUR |
| -0.39 EUR |
| - |
| 111.9 Mio. EUR |
| -28.94 Mio. EUR |
| 20.68 |
| - |
| 24.27% |
| - |
| - |
| - |
| - |
| ANAVEX |
| 25.02.26 |
|
||||
|